Verastem Oncology prices $250 million common stock and pre-funded warrant offering
VSTM•Verastem priced an underwritten offering of 30,937,500 common shares at $8.00 each and pre-funded warrants for 312,503 shares at $7.9999 each, with a $0.0001 exercise price. Gross proceeds are expected to total about $250 million before fees.
1. Offering details
Verastem priced an underwritten offering of 30,937,500 common shares at $8.00 per share and pre-funded warrants for 312,503 shares at $7.9999 each. The warrants have an exercise price of $0.0001. Gross proceeds are expected to total about $250 million before fees.
2. Use of proceeds
Verastem plans to use net proceeds for clinical development, including its VS-7375 program, working capital and general corporate purposes. Closing is targeted for about Oct. 15, 2026, subject to customary conditions.
